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1  | INTRODUC TION
Ménière's disease is a chronic idiopathic condition affecting the 
inner ear that results in repeated episodes of vertigo. The dura-
tion of a characteristic episode of vertigo is between twenty min-
utes and twelve hours according to contemporary classification 
systems.1,2 Advancements in the field of vestibular telemetry have 
allowed the continuous ambulatory assessment of individuals with 
dizziness, vertigo and balance disturbance.3,4 This article outlines 
the findings from assessing three patients with Ménière's disease 
and discusses how the use of vestibular telemetry aided their 
management.
2  | MATERIAL S AND METHODS
2.1 | Trial design
This study was designed and conducted according to the Declaration 
of Helsinki of 1975, as revised in 1983, and was reviewed by the 
London - Dulwich Research Ethics Committee (IRAS Number: 
261 099). This report details the outcomes from preliminary trials 
using the CAVA® (Continuous Ambulatory Vestibular Assessment) 
system. This trial is an interventional clinical investigation to formally 
evaluate the capability of the CAVA® system to detect pathological 
nystagmus.
2.2 | Participants
Eligible participants were adults aged 18 or over, experiencing epi-
sodes of true vertigo, with at least two episodes within the preced-
ing month. This report relates to three patients.
2.3 | Interventions
The CAVA® system is composed of a piece of wearable technol-
ogy, the CAVA® device (Figure 1), plus the algorithms necessary 
to analyse the data it records. Detailed information regarding the 
CAVA® system is available elsewhere,3,4 but in essence, it allows 
the near-continuous monitoring of eye and head movements of 
individuals experiencing dizziness for up to thirty days at a time. 
Parallels can be drawn between the CAVA® device and the 24-
hour ECG tape that is used to identify cardiac arrhythmias5 and 
ambulatory EEG.6
Each patient wore the CAVA® device during all of their normal 
daily activities, and also during the night, whilst sleeping. Patients 
were allotted an hour per day to remove the device for showering 
and to renew the device's electrodes. If patients experienced an ep-
isode of dizziness, they were instructed to press the device's event 
marker button, causing the device to record the date and time of 
the button press. Patients also maintained a written diary of any at-
tacks experienced. At the end of the trial, the event marker data and 
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diary records were used as a starting point from which to explore the 
eye-movement traces for evidence of nystagmus. Once identified vi-
sually, a computer analysis highlighted candidate nystagmus beats 




Patient one was a 53-year-old lady with a fifteen-year history of 
left-sided unilateral Ménière's disease. Discrete episodes of rota-
tory vertigo lasting for hours associated with severe nausea and 
aural fullness in the affected ear had been recently reported. 
Patient one wore the CAVA® device and experienced no issues 
with the device after thirty consecutive days. Upon returning the 
device, the patient reported a single episode of vertigo lasting for 
approximately two hours. Assessing the data confirmed the pres-
ence of nystagmus—see Figure 2. The attack comprised eight pe-
riods of nystagmus, each lasting between approximately 21 and 
460 seconds. Over the course of the attack, the nystagmus direc-
tion alternated from right-beating to left-beating, back to right-
beating, and finally to left-beating. As this confirmed a true acute 
episode of vertigo, a discussion followed regarding the opportuni-
ties for intratympanic therapy.
3.2 | Patient two
Patient two was a sixty-year-old man with a four-year history of 
left-sided unilateral Ménière's disease. He also reported distinct 
episodes of rotatory vertigo lasting for hours associated with se-
vere nausea and aural fullness in the affected ear. Patient two also 
wore the CAVA® device and experienced no issues with the de-
vice after thirty consecutive days. Upon returning the device, he 
reported many episodes of vertigo lasting for merely a few minutes 
at a time. Assessing the data confirmed nystagmus—see Figure 3. 
This trace is very different to that of patient one, as there were 
multiple short periods of nystagmus that often changed direction 
over a period of less than ten seconds. Typically, each burst lasted 
three seconds at most and contained two or three beats of nystag-
mus. Due to the nature of the nystagmus, it was considered that 
patient two was not experiencing typical acute episodes of vertigo 
as would be seen in a typical acute 'Ménière's attack'. The con-
current accelerometer data from the CAVA® device showed that 
the nystagmus was motion provoked, and therefore, suggestive of 
physiological compensation. As such, the patient was offered ves-
tibular rehabilitation.
Keypoints
• Diagnosis of the dizzy patient is challenging because the 
symptoms are momentary and assessment at presenta-
tion is often normal.
• The CAVA® system continuously records 3-axis head 
motions and both horizontal and vertical eye move-
ments during a patient's normal daily activities (day and 
night), and importantly, during episodes of dizziness.
• Vestibular telemetry provided by the CAVA® system can 
be used to differentiate between different causes of diz-
ziness and to assist the clinician in formulating manage-
ment options.
• Vestibular telemetry can clarify a patient's understand-
ing of their own symptoms. This is important, as find-
ings can vary greatly, despite a similar presentation of 
symptoms.
• Vestibular telemetry for individuals with a history of 
Ménière's disease can be very helpful in understanding 
the cause of recent episodes of dizziness and to formu-
late an appropriate treatment plan.
F I G U R E  1   A depiction of the CAVA® device when worn on the face. A reusable logging module sits behind the left ear, and two single-
use electrode mounts attach to the face. The mounts contain five ECG electrode pads, facilitating the capture of both horizontal and vertical 
eye movements. An “event marker” button on the logging module allows patients to log events of interest (eg the onset of dizziness). The 
device also captures head movement by way of a 3-axis accelerometer
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3.3 | Patient three
Patient three was a 39-year-old man with a one-year history of 
left-sided unilateral Ménière's disease. He reported distinct epi-
sodes of rotatory vertigo lasting for hours associated with severe 
nausea and aural fullness in the affected ear in a similar manner to 
the first two patients. Patient three wore the CAVA® device and 
experienced no issues with the device after thirty consecutive 
days. Upon returning the device, he reported multiple episodes of 
almost daily vertigo lasting from between a few minutes to a few 
hours at a time. Assessing the data did not identify any episodes 
of nystagmus—see Figure 4. This trace is very different to that 
of patient one and patient two, as there were no definitive ex-
amples of nystagmus. When this was discussed with the patient, 
his history of symptoms evolved, whereby he provided a fuller 
and more detailed description of the history of his symptoms, and 
in doing this revealed that he does suffer with severe anxiety. 
He realised that it was possible he might actually be experiencing 
panic attacks at work rather than the true, severe and prolonged 
periods of vertigo that he had experienced in the past. Further 
questioning confirmed that these dizzy episodes were more in 
keeping with anxiety rather than with a disturbance of the ves-
tibular system. As such, appropriate management of the patient's 
anxiety was arranged in collaboration with the patient's general 
practitioner.
4  | DISCUSSION
4.1 | Strengths of the study
The CAVA® system has been developed to address the problem that 
individuals with dizziness, vertigo and balance disorders experience 
short-lived episodic symptoms and present with little if any objec-
tive signs when they are assessed in a clinical environment. Parallels 
can be drawn between the CAVA® system and technology employed 
in other clinical fields such as cardiology and neurology.5,6
4.2 | Synopsis of key findings
All three patients presented with similar symptoms but had very 
different findings. Of particular interest was how, when the system 
outputs were presented to each patient, they reported that they 
considered our explanation to support their ability to describe ex-
actly what they were experiencing during an episode of apparent 
“vertigo.” For the two patients whose recorded attacks were not 
typical of Ménière's disease, this subsequently led to a discussion 
during which they revised the description of their dizziness experi-
ence. For the patient who did experience a typical attack, the data 
captured led to a detailed discussion with her regarding the timeline 
and features of their attack.
F I G U R E  2   A 30-second extract from the horizontal eye-movement trace captured during a Ménière's attack reported by patient one. 
The trace shows clear evidence of left-beating nystagmus. The nystagmus beats were automatically detected by a computer algorithm and 
then manually corrected by an expert
F I G U R E  3   The top panel shows a 30-second extract from the horizontal eye-movement trace captured during an attack of dizziness 
reported by patient two. The trace shows short bursts of nystagmus which alternate between left- and right-beating within the time period 
shown. The nystagmus beats were automatically detected by a computer algorithm and then manually corrected by an expert. The bottom 
panel shows the concurrent 3-axis accelerometer data and reveals that the patient is moving their head during the dizzy attack
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4.3 | Clinical applicability of the study
In addition to clarifying patient symptoms, outputs from the CAVA® 
system are likely to provide further insight into the underlying 
mechanisms affecting the vestibular system for conditions such as 
Ménière's disease. From a fundamental clinical perspective, this 
would aid the identification of Ménière's disease and its subtypes, 
such as bilateral disease, to allow the correct determination of the 
active ear and thereby facilitate decisions regarding the appropriate 
treatment.
4.4 | Comparisons with other studies
Much is unknown regarding the aetiology of Ménière's disease but 
having a tool to record the neurophysiological activity of the ves-
tibular system during disease activity allows a unique opportunity 
to study this. Whilst there have been a number of isolated reports 
documenting eye movements of Ménière's disease patients during 
an acute attack of vertigo, these have been opportunistic ventures, 
and have only captured relatively small periods of nystagmus.7 More 
recently, video technology has been offered in the community in 
which goggles are supplied to patients with the instruction to wear 
them when a dizzy attack is anticipated.8 Young et al provide an im-
pressive record of experience with such patients. However, it is not 
possible to wear the goggles continuously, and they do not record 
information prior to and after an attack. Furthermore, the use of 
videonystagmography (VNG) rather than electronystagmography 
(ENG) requires a patient who is just beginning to experience an acute 
vertigo attack to be able to gather their thoughts, remember where 
their goggles are stored, switch them on and then fit them correctly. 
The approach adopted for the CAVA® device, ENG, avoids these 
practical challenges and enables the device to be worn throughout 
the night. It also functions with the eyes open and closed.
4.5 | Limitations of the study and further work
At this stage of our research program, the automatic detection 
of nystagmus in eye-movement signals has been validated only 
for physiologically induced nystagmus in the horizontal plane.3,4 
Pathological nystagmus is quite different from the physiologically 
induced nystagmus analysed previously, as it is highly variable in 
terms of signal amplitude and frequency. Despite this, pathologi-
cal nystagmus is clearly discernible in the data collected by the 
CAVA® device. In view of this, a semi-automatic approach was 
adopted here. Following this work and using the data presented, 
we are currently developing computer algorithms that use cutting-
edge Neural Network techniques to detect periods of pathological 
nystagmus, including nystagmus present in the vertical plane, such 
as that produced by patients with Benign Paroxysmal Positional 
Vertigo. Upon the completion of our current clinical investigation, 
we will formally evaluate our algorithm's accuracy at detecting 
these different forms of pathological nystagmus. Our long-term 
goal is to develop reliable detection algorithms for pathological 
nystagmus to further allow the determination of aetiology via ma-
chine learning approaches.
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